Ownership and insider activity for Nexalin Technology, Inc. (NXL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia.
Price
| Price | $4.92 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-12-19 | White Mark | A-Award | 1,000,000 | $830K |
| 2025-12-19 | Van Fleet Justin | A-Award | 100,000 | $83K |
| 2025-12-19 | Owens David | A-Award | 1,000,000 | $830K |
| 2025-12-19 | Shelton Carolyn Hamby | A-Award | 100,000 | $83K |
| 2025-12-19 | Hu Ben | A-Award | 100,000 | $83K |
| 2025-12-19 | Kazden Alan | A-Award | 100,000 | $83K |
| 2025-09-29 | OSSER LEONARD | A-Award | 83,333 | |
| 2025-09-29 | Owens David | A-Award | 36,459 | |
| 2025-09-29 | Hu Ben | A-Award | 36,459 | |
| 2025-09-29 | Kazden Alan | A-Award | 36,459 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63427 | $78436 | $661778 | $162743 | $580230 | $574485 | $654783 |
| Short-term Investments | 0 | 0 | 0 | $6.8M | $2.4M | $2.9M | $3.1M |
| Receivables | $5690 | $6599 | $16303 | $4875 | $9369 | $13043 | $81571 |
| Inventory | $21598 | $22656 | $31410 | $154370 | $156420 | $174578 | $131473 |
| Total Current Assets | $111149 | $116885 | $752659 | $7.4M | $3.4M | $4.0M | $4.3M |
| Property, Plant & Equipment | $1357 | $1576 | $1039 | $6674 | $496 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $105528 | $260727 | $336049 |
| Total Assets | $112506 | $118461 | $753698 | $7.4M | $3.6M | $4.2M | $4.6M |
| Accounts Payable | $324470 | $461161 | $843794 | $658367 | $159534 | $155949 | $244579 |
| Short-term Debt | $551667 | $546800 | $737200 | $700000 | 0 | 0 | 0 |
| Total Current Liabilities | $1.0M | $1.6M | $2.4M | $1.9M | $425281 | $546694 | $887333 |
| Long-term Debt | $154816 | $52305 | $22916 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.3M | $1.7M | $2.4M | $2.0M | $425281 | $546694 | $887333 |
| Retained Earnings | -$61.2M | -$64.6M | -$70.7M | -$72.4M | -$77.0M | -$84.6M | -$92.9M |
| Total Equity | -$1.2M | -$1.6M | -$1.7M | $5.5M | $3.2M | $3.7M | $3.7M |
| Total Debt | $826766 | $726012 | $850050 | $755260 | $4463 | 0 | 0 |
| Net Debt | $763339 | $647576 | $188272 | -$6.2M | -$2.9M | -$3.5M | -$3.7M |
| Working Capital | -$930730 | -$1.4M | -$1.6M | $5.5M | $3.0M | $3.4M | $3.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.25 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -26.89 |
Profitability
| Return on Equity | -278.25% |
| Return on Invested Capital | -600.62% |
| Return on Assets | -299.21% |
| Gross Margin | -148.42% |
| Operating Margin | -4202.54% |
| Net Margin | -4139.38% |
Related companies: CLGN · ENLV · HBIO · IINN · MODD · NRXS · RBOT
Explore sector: Healthcare · Medical - Devices
More sections of NXL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks